Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

Research output: Contribution to journalArticlepeer-review

245 Citations (Scopus)
Original languageEnglish
JournalLancet
DOIs
Publication statusPublished - 2013

Cite this